clinical endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
==== Structure ==== The myophosphorylase structure consists of 842 amino acids. The molecular weight of the unprocessed precursor is 97 kDa. The three-dimensional structure has been determined for this protein. The interactions of several amino acids in myophosphorylase's structure are known. Ser-14 is modified by phosphorylase kinase during activation of the enzyme. Lys-680 is involved in binding the pyridoxal phosphate, which is the active form of vitamin B6, a cofactor required by myophosphorylase. By similarity, other sites have been estimated: Tyr-76 binds AMP, Cys-109 and Cys-143 are involved in subunit association, and Tyr-156 may be involved in allosteric control.
The 1923 constitution was drawn up in non-racial terms, and the electoral system it devised was similarly open, at least in theory. Voting qualifications regarding personal income, education and property, similar to those of the Cape Qualified Franchise, were applied equally to all, but since most blacks did not meet the set standards, both the electoral roll and the colonial parliament were overwhelmingly from the white minority of about 5%. The result was that black interests were sparsely represented if at all, something that most of the colony's whites showed little interest in changing; they claimed that most blacks were uninterested in Western-style political process and that they would not govern properly if they took over. Bills such as the Land Apportionment Act of 1930, which earmarked about half of the country for white ownership and residence while dividing the rest into black purchase, tribal trust and national areas, were variously biased towards the white minority. White settlers and their offspring provided most of the colony's administrative, industrial, scientific and farming skills, and built a relatively balanced, partially industrialised market economy, boasting strong agricultural and manufacturing sectors, iron and steel industries and modern mining enterprises. Everyday life was marked by discrimination ranging from job reservation for whites to petty segregation of trains, post office queues and the like.
=== Eyelid layers === The eyelid consists of multiple layers, including the skin, subcutaneous tissue, orbicularis oculi muscle, orbital septum, orbital fat, tarsal plate, and conjunctiva. The skin is thin and prone to redundancy with age, while the orbital septum helps contain the orbital fat, which may protrude and contribute to eyelid "bags."
Sources: en.wikipedia.org
The life of an ant starts from an egg. If the egg is fertilized, the progeny will be female diploid; if not, it will be male haploid. Ants develop by complete metamorphosis with the larva stages passing through a pupal stage before emerging as an adult. The larva is largely immobile and is fed and cared for by workers. Food is given to the larvae by trophallaxis, a process in which an ant regurgitates liquid food held in its crop. This is also how adults share food, stored in the "social stomach". Larvae, especially in the later stages, may also be provided solid food, such as trophic eggs, pieces of prey, and seeds brought by workers. The larvae grow through a series of four or five moults and enter the pupal stage. The pupa has the appendages free and not fused to the body as in a butterfly pupa. The differentiation into queens and workers (which are both female), and different castes of workers, is influenced in some species by the nutrition the larvae obtain. Genetic influences and the control of gene expression by the developmental environment are complex and the determination of caste continues to be a subject of research. Winged male ants, called drones (termed "aner" in old literature), emerge from pupae along with the usually winged breeding females. Some species, such as army ants, have wingless queens. Larvae and pupae need to be kept at fairly constant temperatures to ensure proper development, and so often are moved around among the various brood chambers within the colony.
=== HIV long-term nonprogressors === About 1 in 500 people infected with HIV can remain symptom-free for many years without medication, a group known as long-term nonprogressors. The presence of HLA-B27, as well as HLA-B5701, is significantly common among this group.
HPG is synthesized from prephenate, an intermediate in the shikimic acid pathway and also a precursor to tyrosine. Prephenate is aromatized by prephenate dehydrogenase (Pdh) using NAD+ as a cofactor to produce 4-hydroxyphenylpyruvate. 4-Hydroxyphenylpyruvate is then oxidized by 4-hydroxymandelate synthase (4HmaS) using oxygen to form 4-hydroxymandelate and hydrogen peroxide. 4HmaS is a non-heme iron-dependent dioxygenase. The reaction mechanism of this unique oxidation was proposed by Choroba et al in 2000
Sources: en.wikipedia.org
=== Studies indicating negligible effects === Studies in 2005 and earlier have concluded that DU ammunition has no measurable detrimental health effects. A 1999 literature review conducted by the Rand Corporation stated: "No evidence is documented in the literature of cancer or any other negative health effect related to the radiation received from exposure to depleted or natural uranium, whether inhaled or ingested, even at very high doses," and a RAND report authored by the U.S. Defense department undersecretary charged with evaluating DU hazards considered the debate to be more political than scientific. A 2001 oncology study concluded that "the present scientific consensus is that DU exposure to humans, in locations where DU ammunition was deployed, is very unlikely to give rise to cancer induction". Former NATO Secretary General Lord Robertson stated in 2001 that "the existing medical consensus is clear. The hazard from depleted uranium is both very limited, and limited to very specific circumstances". A 2002 study from the Australian defense ministry concluded that "there has been no established increase in mortality or morbidity in workers exposed to uranium in uranium processing industries...
=== Locus coeruleus–noradrenergic system === This theory hypothesizes that autistic behaviors depend at least in part on a developmental dysregulation that results in impaired function of the locus coeruleus–noradrenergic (LC-NA) system. The LC-NA system is heavily involved in arousal and attention; for example, it is related to the brain's acquisition and use of environmental cues.
Evidence of application of poison derived from plants (likely from Boophone disticha) on the tips of 60,000-years-old arrowhead from the Umhlatuzana Rock Shelter (South Africa) is presented by Isaksson, Högberg & Lombard (2026). Arlt (2026) determines the Robberg stone tool tradition in southern Africa to span the internal from 24.800 to 9.700 years ago rather than from 18.000 to 12.000 years ago, and reports evidence of a more gradual transition between Robberg and Oakhurst technocomplexes than indicated by earlier studies. Review of research on the origin and on the course of global spread of Homo sapiens out of Africa from the preceding years is published by Groucutt (2026). Pantoja-Pérez et al. (2026) identify dental and bone abnormalities in the mandible of Qafzeh 25 as likely caused by sharp object trauma, and report evidence of survival of the studied individual after the injury. Litov, Ben-Dor & Barkai (2026) interpret the decline of use of in heavy-duty tools in Levant after the Lower-Middle Paleolithic transition, coinciding with decline of megaherbivores in the studied region, as indicating that the studied tools were primarily used for processing of large prey. Abbas et al. (2026) provide evidence from the study of riverine wetland environments from the Hamra Faddan and Wadi al-Hasa localities from the eastern margin of the Jordan Rift Valley interpreted as indicating that southern Levant provided a stable environmental niche that sustained human populations from the late Middle Paleolithic to the Upper Paleolithic. Zhao et al.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.